Igor Puzanov, MD, MSCI, FACP, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses advances in interleukin-2 (IL-2) therapeutics, with some setbacks seen in bempegaldesleukin (NKTR-214). The emergence of newly modified cytokine therapies like WTX-124 shows promise due to improved stability and a masking domain that prevents activation in the bloodstream. Instead, tumor-specific proteases cleave the masking domain, allowing IL-2 activation within the tumor microenvironment. Pharmacokinetic data indicate favorable absorption with increasing doses. In the clinic, WTX-124 will undergo evaluation in combination with pembrolizumab for patients with refractory melanoma, renal cell carcinoma, squamous-cell skin, and esophageal cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть